Pulmonary embolism - An update on thrombolytic therapy

QJM: An International Journal of Medicine

Volumn 93, Issue 5, 2000, Pages 261-267

  Thomas, M D ^a   Chauhan, A ^b   More, R S ^a  

^a ST MARY S HOSPITAL   (United Kingdom)

^b BLACKPOOL VICTORIA HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACENOCOUMAROL; ALTEPLASE; ANTICOAGULANT AGENT; FIBRINOLYTIC AGENT; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; OPIATE DERIVATIVE; OXYGEN; PLACEBO; STREPTOKINASE; UROKINASE; WARFARIN;

BLEEDING; CARDIOPULMONARY HEMODYNAMICS; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE PREDISPOSITION; DOSE RESPONSE; DRUG EFFICACY; ECHOCARDIOGRAPHY; FIBRINOLYTIC THERAPY; HUMAN; LUNG ANGIOGRAPHY; LUNG EMBOLISM; PRIORITY JOURNAL; REVIEW; SPIRAL COMPUTER ASSISTED TOMOGRAPHY; THROMBOEMBOLISM; TREATMENT FAILURE;

EID: 0034022627     PISSN: 14602725     EISSN: None     Source Type: Journal    
DOI: 10.1093/qjmed/93.5.261     Document Type: Review

References (54)

1. Linblad B, Sternby WH, Bergquist D. Incidence of venous thromboembolism verified by necropsy over 30 years. Br Med J 1991; 302:709-11.
2. Wessler S. Prevention of venous thromboembolism: Rationale, Practice and Problems, NIH 1986 Consensus Development Conference on Prevention of Venous Thrombosis and Pulmonary Embolism. National Institutes of Health, Bethesda, Maryland, 1986.
3. Stein PD, Henry JW. Prevalence of acute pulmonary embolus among patients in a general hospital and at autopsy. Chest 1995; 108:978-81.
4. Modan B, Sharon E, Jelin N. Factors contributing to the incorrect diagnosis of pulmonary embolic disease. Chest 1972; 62:388-93.
5. Saeger W, Genzkow M. Venous thromboses and pulmonary embolisms in post-mortem series: probable causes by correlations of clinical data and basic diseases. Pathol Res Pract 1994; 190:394-9.
6. Clagett GP, Anderson FA, Heit J, Levine MN, Wheeler HB. Prevention of venous thromboembolism. Chest 1995; 108(4 Suppl):312-34S.
7. Hyers TM, Agnelli G, Hull R, Weg JG, Morris TA, Samama M, Tapson V. Antithrombotic therapy for venous thromboembolic disease. Chest 1998; 114:561-78S.
8. Goldhaber SZ, Braunwald E. Tissue plasminogen activators in the treatment of acute pulmonary embolism. In: Sobel BE, Collen D, Grossbard EB, eds. Tissue plasminogen activator in thrombolytic therapy. Basel, Marcel Dekker, 1987:147-69.
9. Porter RS, Dipalma JR. Thrombolysis for pulmonary embolism. Am Fam Physician 1991; 44:1365-70.
10. Heitz JA. An analysis of current pulmonary embolism therapy. Int Angiol 1992; 11:57-63.
11. Ribeiro A, Lindmarker P, Johnsson H, Julin-Dannfelt A, Jorfeldt L. Pulmonary embolism: one-year follow-up with echocardiography doppler and five-year survival analysis. Circulation 1999; 99:1325-30.
12. Barritt DW, Jordan SC. Anticoagulant drugs in the treatment of pulmonary embolism. Lancet 1960; 1:1309-12.
13. Simonneau G, Sors H, Charbonnier B, Page Y, Laaban JP, Azarian R, Laurent M, Hirsch JL, Ferrari E, Bosson JL, Mottier D, Beau B. A comparison of low-molecular-weight heparin with unfractionated heparin for acute pulmonary embolism. The THESEE Study Group. Tinzaparine ou Heparine Standard: Evaluations dans l'Embolie Pulmonaire. N Engl J Med 1997; 337:663-9.
14. Meyer G, Brenot F, Pacouret G, Simmoneau G, Juvin KG, Charbonnier B, Sors H. Subcutaneous low-molecular weight heparin fragmin versus intravenous unfractionated heparin in the treatment of acute non massive pulmonary embolism: an open randomised pilot study. Thromb Haemost 1995; 74:1432-5.
15. Gulba DC, Schmid C, Borst H-G, Lichtlen P, Dietz R, Luft FC. Medical compared with surgical treatment for massive pulmonary embolism. Lancet 1994; 343:576-7.
16. Dalen JE, Banas JS, Brooks HC, Evans GL, Paraskos JA, Dexter L. Resolution rate of acute pulmonary embolism in man. N Engl J Med 1969; 280:1194-8.
17. Tow DE, Wagner NH. Recovery of pulmonary artery flow in patients with pulmonary embolism. N Engl J Med 1967; 276:1053-6.
18. Thrombolytic therapy in thrombosis: A National Institutes of Health Consensus Development Conference. Ann Intern Med 1980; 93:141-68.
19. Hirsh J, Hale GS, McDonald TG, McCarthy RA, Pitt A. Streptokinase therapy in acute major pulmonary embolism: effectiveness and problems. Br Med J 1968; 4:729-34.
20. Kakkar VV, Raftery EB. Selection of patients with pulmonary embolism for thrombolytic therapy. Lancet 1970; 2:237-41.
21. Miller GA, Sutton GC, Kerr IH, Gibson RV, Honey M. Comparison of streptokinase and heparin in treatment of isolated acute massive pulmonary embolism. Br Med J 1971; 2:681-4.
22. The UKEP Study Research Group. The UKEP study: rnulticentre clinical trial on two local regimens of urokinase in massive pulmonary embolism. Eur Heart J 1987; 8:2-10.
23. Griguer P, Charbonnier B, Latour F, Fauchier JP, Brochier M. Plasminogen and moderate doses of urokinase in the treatment of acute pulmonary embolism. Angiology 1979; 30:1-12.
24. Edwards IR, MacLean KS, Dow JD. Low dose urokinase in major pulmonary embolism. Lancet 1973; 2:409-13.
25. The Urokinase Pulmonary Embolism Trial Study Group. The urokinase pulmonary embolism trial: a national cooperative study. Circulation 1973: 47(2 Suppl):II 1-108.
26. Hirsh J, McDonald IG, Hale GA, O'Sullivan EF, Jelinek VM. Comparison of the effects of streptokinase and heparin in the early rate of resolution of major pulmonary embolism. Can Med Assoc J 1971; 104:488-91.
27. Sharma GVRK, Burleson VA, Sasahara AA. Effect of thrombolytic therapy on pulmonary-capillary blood volume in patients with pulmonary embolism. N Engl J Med 1980; 303:842-5.
28. Tibbutt DA, Davies JA, Anderson JA, Fletcher EW, Hamill J, Holt JM, Thomas ML, Lee g, Miller GA, Sharp AA, Sutton GC. Comparison by controlled clinical trial of streptokinase and heparin in the treatment of life threatening pulmonary embolism. Br Med J 1974; 1:343-7.
29. Ly B, Arnesen H, Eie H, Hol R. A controlled clinical trial of streptokinase and heparin in the treatment of major pulmonary embolism. Acta Med Scand 1978; 203:465-70.
30. The PIOPED Investigators. Tissue plasminogen activator for the treatment of acute pulmonary embolism. A collaborative study by the PIOPED Investigators. Chest 1990; 97:528-33.
31. Boumanameaux H, Vermylen J, Collen D. Thrombolytic treatment with recombinant tissue-type plasminogen activator in a patient with massive pulmonary embolism. Ann Intern Med 1985; 103:64-6.
32. Coldhaber SZ, Haire WD, Feldstein ML, Miller M, Toltzis R, Smith JL, Taveira AM, Come PC, Lee RT, Parker JA. Alteplase versus heparin in acute pulmonary embolism: randomised trial assessing right-ventricular function and pulmonary perfusion. Lancet 1993; 341:507-11.
33. Konstantinides S, Geibel A, Olschewski M, Heinrich F, Grosser K, Rauber K, Iversen S, Redecker M, Kienast J, Just H, Kasper W. Association between thrombolytic treatment and the prognosis of haemodynamically stable patients with major pulmonary embolism: results of a multicentre registry. Circulation 1997; 96:882-8.
34. Korninger C, Matsuo O, Suy R, Stassen JM, Collen D. Thrombolysis with human extrinsic (tissue type) plasminogen activator in dogs with femoral vein thrombosis. J Clin Invest 1983; 71:368-76.
35. Agnelli G, Buchanan MR, Fernandez F, Boneau B, Van Ryn J, Hirsh J, Collen D. A comparison of the thrombolytic and haemorrhagic effects of tissue-type plasminogen activator and streptokinase in rabbits. Circulation 1985; 72:178-82.
36. Goldhaber SZ, Vaughan DE, Markis JE, Selwyn AP, Meyerovitz MF, Loscalzo J, Kim DS, Kessler CM, Dawley DL, Sharma GV. Acute pulmonary embolism treated with tissue plasminogen activator. Lancet 1986; 2:886-9.
37. Urokinase-Streptokinase embolism trial. Phase 2 results. A cooperative study. JAMA 1974; 229:1606-13.
38. Goldhaber SZ, Kessler CM, Heit JA, Elliott CG, Friedenberg WR, Heiselman DE, Wilson DB, Parker JA, Bennett D, Feldstein MI. Recombinant tissue-type plasminogen activator versus a novel dosing regimen of urokinase in acute pulmonary embolism: a randomised controlled multicenter trial. J Am Coll Cardiol 1992; 20:24-30.
39. Meyer GM, Sors H, Charbonnier B, Kasper W, Bassand JP, Kerr IH, Lesaffre E, Vanhove P, Verstraete M. Effects of intravenous urokinase versus alteplase on total pulmonary resistance in acute massive pulmonary embolism: A European multicentre double-blind trial. The European Cooperative Study Group for Pulmonary Embolism. J Am Coll Cardiol 1992; 19:239-45.
40. British Thoracic Society, Standard of Care Committee. Suspected acute pulmonary embolism: a practical approach. Thorax 1997; 52(Suppl 4):S1-24.
41. Meneveau N, Schiele F, Mertz D, Valette B, Attali P, Vuillemenot A, Grollier G, Elaerts J, Mossard JM, Viel JF, Bassand JP. Comparative efficacy of a two-hour regimen of streptokinase versus alteplase in acute massive pulmonary embolism: immediate clinical and haemodynamic outcome and one-year follow-up. J Am Coll Cardiol 1998; 31:1057-63.
42. Levine MN. Bolus, front-loaded, and accelerated thrombolytic infusions for myocardial infarction and pulmonary embolism. Chest 1991; 99(4 Suppl):128S-34S.
43. Levine M, Hirsh J, Weitz J, Cruickshank M, Neemeh J, Turpie AG, Gent M. A randomised trial of a single bolus dosage regimen of recombinant tissue plasminogen activator in patients with acute pulmonary embolism. Chest 1990; 98:1473-9.
44. Diehl JL, Meyer G, Igual J, Collignon MA, Giselbrecht M, Even P, Sors H. Effectiveness and safety of bolus administration of alteplase in massive pulmonary embolism. Am J Cardiol 1992; 70:1477-80.
45. Petitpretz P, Simmoneau G, Cerrina J, Musset D, Dreyfus M, Vandenbroek MD, Duroux P. Effects of a single bolus of urokinase in patients with life-threatening pulmonary emboli: a descriptive trial. Circulation 1984; 70:861-6.
46. Stern M, Meyer G, Sors H. Urokinase versus tissue plasminogen activator in pulmonary embolism (letter). Lancet 1988; 2:691-2.
47. Tibbutt DA, Davies JA, Miller GA, Sutton GC, Sharp AA, Lee G, Holt M, Kakkar VV, Flute PT. Comparison between streptokinase and heparin in life-threatening pulmonary embolism. Br J Haematol 1973; 25:275-6.
48. Mavor GE, Harper DR, Woodruff PW. Treatment of massive pulmonary embolism (letter). Br Med J 1973; 1:175-6.
49. Rosenthal D, Evans, Borrero E, Lamis PA, Clark MD, Daniel WW. Massive pulmonary embolism: triple armed therapy. J Vasc Surg 1989; 9:261-70.
50. Vujic I, Young JW, Gobien RP, Dawson WT, Liebscher L, Shelley BE. Massive pulmonary embolism: treatment with full heparinization and topical low-dose streptokinase. Radiology 1983; 48:671-5.
51. Mohindra SK, Udeani GO. Treatment of massive pulmonary embolism with centrally administered tissue type plasminogen activator. Ann Emerg Med 1993; 22:1349-52.
52. Verstraete M, Miller GAH, Bounameaux H, Charbonnier B, Colle JP, Lecorf G, Marbet GA, Mombaerts P, Olsson PG. Intravenous and intrapulmonary recombinant tissue-type plasminogen activator in the treatment of acute massive pulmonary embolism. Circulation 1988; 77:353-60.
53. Meneveau N, Bassand JP, Schiele F, Bouras Y, Anguenot T, Bernard Y, Schultz R. Safety of thrombolytic therapy in elderly patients with massive pulmonary embolism: a comparison with non-elderly patients. J Am Coll Cardiol 1993; 22:1075-9.
54. Gemmill JD, Hogg KJ, Dunn FG, Rae AP, Hillis WS. Predosing antibody levels and efficacy of thrombolytic drugs containing streptokinase. Br Heart J 1994; 72:222-5.